Methotrexate Maintenance After Initiation of Biological or Targeted Synthetic DMARDs in Rheumatoid Arthritis: Results from the 2-Year Longitudinal Prospective Non-interventional STRATEGE2 Study
ClinicalTrials.gov: Therapeutic Strategy Associated with bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis (STRATEGE2), NCT05082805.
Authors
- H. Herman-Demars (ORCID: https://orcid.org/0009-0000-3780-9418)
- Éric Senbel (ORCID: https://orcid.org/0009-0001-6290-6110)
- Emmanuelle Dernis (ORCID: https://orcid.org/0000-0001-6113-166X)
- C. Gaujoux-Viala (ORCID: https://orcid.org/0000-0002-2099-6496)
- René‐Marc Flipo (ORCID: https://orcid.org/0000-0001-5528-8070)
- Jennifer Becker (ORCID: https://orcid.org/0009-0004-8554-4281)
Institutions
- Inserm (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Specialty Materials (United States) (US)
- Nordic Pharma (France) (FR)
- Hôpital Roger Salengro (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Institute for Neurosciences of Montpellier (FR)
- Université de Nîmes (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1007/s40744-025-00806-1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nordic Pharma Group